ReviewBMC medicine2015
New players in the preventive treatment of migraine.
Review in BMC medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.Journal of neurology · 2020Pooled it
- Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study.The journal of headache and pain · 2017Trial
- Article
- Vitamin D in Neurological Diseases.International journal of molecular sciences · 2022Review
- Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.Frontiers in pharmacology · 2022Article
- Riboflavin in Neurological Diseases: A Narrative Review.Clinical drug investigation · 2021Review
- Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.The Journal of pharmacy and pharmacology · 2020Article
- Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.The journal of headache and pain · 2019Article
- Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.Drugs · 2018Review
- Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache.Cephalalgia : an international journal of headache · 2018Article
- Patients' preferences for headache acute and preventive treatment.The journal of headache and pain · 2017Article
- Review
- Diclofenac potassium for oral solution (CAMBIATherapeutic advances in neurological disorders · 2017Review
- Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.Journal of pain research · 2017Review
- Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.Headache · 2017Review
- The Molecular Fingerprint of Dorsal Root and Trigeminal Ganglion Neurons.Frontiers in molecular neuroscience · 2017Article
- Neurovascular contributions to migraine: Moving beyond vasodilation.Neuroscience · 2016Review
- Anti-CGRP monoclonal antibodies in migraine: current perspectives.Internal and emergency medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common, chronic disorder of the brain causing much disability, as well as personal, familial and societal impact. Several oral preventive agents are available in different countries for the prevention of migraine, but none have performed better than 50% improvement in 50% of patients in a clinical trial. Additionally, each has various possible adverse events making their tolerability less than optimal. Recently, three monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) ligand (LY2951742, ALD403 and TEV-48125) and one targeting the CGRP receptor (AMG 334) have completed phase 2 trials, and the results have been reported. These early results show them all to be somewhat more effective than placebo, with no serious adverse events. Three have been studied for episodic migraine, and only TEV-48125 has been studied for both high frequency episodic and chronic migraine. Moreover, preliminary data suggests that neurostimulation is effective in migraine treatment, including stimulation of the sphenopalatine ganglion, transcutaneous supraorbital and supratrochlear nerve, and transcutaneous vagus nerve. In this article, these innovative therapies will be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.